Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Abstract:
Quintessence today announced that data for their lead EVade™ Ribonuclease, called QBI-139, will be presented at the American Society of Clinical Oncology 46th Annual Meeting.

Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Madison, WI | Posted on June 7th, 2010

QBI-139 is a protein therapeutic that targets the RNA in cancer cells. The data from abstract TPS162 will be presented at 8 AM on Monday June 7, 2010. The focus will be on the design of the Phase I clinical trial of QBI-139. QBI-139 has shown broad single agent activity against a variety of cancer models addressing significant unmet need, such as non-small cell lung and pancreatic cancers.

####

About Quintessence Biosciences
Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of cancer therapies based on the proprietary EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is in a Phase 1 clinical trial at The University of Texas M.D. Anderson Cancer Center and The University of Wisconsin Carbone Cancer Center. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About the American Society of Clinical Oncology
The 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) is being held in Chicago, June 4-8, 2010. This year's Annual Meeting will focus on Advancing Quality through Innovation. More than 30,000 cancer specialists from around the world will gather to discuss the latest innovations in research, quality, practice and technology in cancer. For more information, visit chicago2010.asco.org/Home.aspx

About the ASCO Annual Meeting Trials in Progress Poster Session
The objective of the Trials in Progress Poster Session is to publicize ongoing phase I or phase II trials and stimulate discussion and participation among peers. The posters discuss the science behind the trial, including pre-clinical data. In addition, the posters will describe the trial design and current enrollment status.

For more information, please click here

Contacts:
Dr. Laura Strong
President and Chief Operating Officer
608-441-2950


Copyright © Quintessence Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Chains of nanogold – forged with atomic precision September 23rd, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Nanotech Grants Options September 22nd, 2016

Coffee-infused foam removes lead from contaminated water September 21st, 2016

Nanomedicine

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016

Graphene nanoribbons show promise for healing spinal injuries: Rice University scientists develop Texas-PEG to help knit severed, damaged spinal cords September 19th, 2016

Announcements

Chains of nanogold – forged with atomic precision September 23rd, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Nanotech Grants Options September 22nd, 2016

Coffee-infused foam removes lead from contaminated water September 21st, 2016

Events/Classes

Oxford Instruments is ‘Bringing the Nanoworld Together’ in India once again - 22 - 23 November 2016 | IISc Bangalore September 21st, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016

PHENOMEN is a FET-Open Research Project aiming to lay the foundations a new information technology September 19th, 2016

Nanobiotechnology

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016

Graphene nanoribbons show promise for healing spinal injuries: Rice University scientists develop Texas-PEG to help knit severed, damaged spinal cords September 19th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic